Correlation Between Connect Biopharma and Edgewise Therapeutics
Can any of the company-specific risk be diversified away by investing in both Connect Biopharma and Edgewise Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Connect Biopharma and Edgewise Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Connect Biopharma Holdings and Edgewise Therapeutics, you can compare the effects of market volatilities on Connect Biopharma and Edgewise Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Connect Biopharma with a short position of Edgewise Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Connect Biopharma and Edgewise Therapeutics.
Diversification Opportunities for Connect Biopharma and Edgewise Therapeutics
-0.12 | Correlation Coefficient |
Good diversification
The 3 months correlation between Connect and Edgewise is -0.12. Overlapping area represents the amount of risk that can be diversified away by holding Connect Biopharma Holdings and Edgewise Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Edgewise Therapeutics and Connect Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Connect Biopharma Holdings are associated (or correlated) with Edgewise Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Edgewise Therapeutics has no effect on the direction of Connect Biopharma i.e., Connect Biopharma and Edgewise Therapeutics go up and down completely randomly.
Pair Corralation between Connect Biopharma and Edgewise Therapeutics
Given the investment horizon of 90 days Connect Biopharma Holdings is expected to under-perform the Edgewise Therapeutics. In addition to that, Connect Biopharma is 1.93 times more volatile than Edgewise Therapeutics. It trades about -0.17 of its total potential returns per unit of risk. Edgewise Therapeutics is currently generating about -0.14 per unit of volatility. If you would invest 3,481 in Edgewise Therapeutics on August 24, 2024 and sell it today you would lose (283.00) from holding Edgewise Therapeutics or give up 8.13% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Connect Biopharma Holdings vs. Edgewise Therapeutics
Performance |
| Timeline |
| Connect Biopharma |
| Edgewise Therapeutics |
Connect Biopharma and Edgewise Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Connect Biopharma and Edgewise Therapeutics
The main advantage of trading using opposite Connect Biopharma and Edgewise Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Connect Biopharma position performs unexpectedly, Edgewise Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edgewise Therapeutics will offset losses from the drop in Edgewise Therapeutics' long position.| Connect Biopharma vs. Assembly Biosciences | Connect Biopharma vs. Instil Bio | Connect Biopharma vs. CytomX Therapeutics | Connect Biopharma vs. Achilles Therapeutics PLC |
| Edgewise Therapeutics vs. Lyra Therapeutics | Edgewise Therapeutics vs. Hookipa Pharma | Edgewise Therapeutics vs. Cingulate Warrants | Edgewise Therapeutics vs. SAB Biotherapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |